Organised by: 

Abstract
There is still the need to lower LDL-c, although the use of statins, ezetimibe and proprotein convertase subtilisin/kexin type 9. Patients with atherosclerotic cardiovascular disease and/or familial hypercholesterolaemia are treated with statins at maximum tolerated dose, with or without further lipid-lowering drugs, but very often, we can’t reach the goal, so bempedoic acid treatment lead to a significant reduction in low-density lipoprotein cholesterol, in different groups of patients, with a favourable safety profile.
Contributors

Luca Monzo
Author

Germana Panattoni
Author

Chiara Lanzillo
Author

Marco Rebecchi
Author

Leonardo Calò
Author
You may be interested in
Congress Session
14 April 2023

Congress Presentation

